Business Wire

Quectel response to FCC about IoT module security

7.9.2023 16:03:00 EEST | Business Wire | Press release

Share

Quectel Wireless Solutions, a global IoT solutions provider, today commented on the recent letter and response being published by the FCC and the Select Committee of the US Congress questioning if Quectel’s IoT modules represent a potential security risk.

“We welcome the opportunity to work with the FCC and other U.S. government entities to demonstrate our compliance and best practice device security approach, says Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We are committed to contributing to the advancement of a smarter world by delivering best-in-class and secure products. This commitment is evidenced by our extensive device OEM customer base and our constant focus on providing our customers with the best and most secure modules in the industry.”

The Select Committee to the US Congress’ letter to the FCC had several misconceptions about how Quectel modules work. Quectel’s clarification regarding the statements made in the letter is as follows.

Committee letter: “Connectivity modules are typically controlled remotely and are the necessary link between the device and the internet.”

Quectel’s U.S. customers or their customers’ third-party suppliers/service providers handle device and data management exclusively. Firmware updates are managed and controlled by the device original equipment manufacturer (OEM), not Quectel.

Committee letter: “Serving as the link between the device and the internet, these modules have the capacity both to brick the device and to access the data flowing from the device to the web server that runs each device”

The control of Quectel modules resides with the microcontroller unit (MCU) or central processing unit (CPU) embedded within the customer's device. Quectel itself does not possess any control; instead, this authority rests solely with the OEM – the entity responsible for developing the device. Remote management of the device is achievable solely through the OEM's device management platform. A notable instance of this, referred to in the letter, is the widely covered case involving John Deere agricultural equipment, where just the OEM typically can disable the equipment by accessing and shutting down its own MCU’s controlling the machine.

Committee letter: “As a result, if the CCP can control the module, it may be able to effectively exfiltrate data or shut down the IoT device.”

Once Quectel modules leave the factory and are delivered to its customers, Quectel customers own the data, and Quectel has no access to any of the data collected. The ownership, control, storage, and modification of the data generated by IoT devices within the market firmly rest with the OEM device makers and its customers. Even in the rare cases outside of the U.S. where Quectel resells the connectivity service of a wireless carrier, Quectel does not have access to the device data.

Committee letter: “This raises particularly grave concerns in the context of critical infrastructure and any type of sensitive data.”

Applications that require high security, such as critical infrastructure, typically use private access point names (APNs) and other methods which strictly control and monitor network access. This can be used to control and monitor any data flowing to and from the device. Critical infrastructure is meticulously fashioned with a multi-tiered security approach defined and implemented solely by the device OEM, not Quectel.

The cellular industry is heavily regulated and requires intensive testing and accreditation. Carrier and regulatory certifications are executed by trusted third-party labs and carrier labs, assuring that the module complies with strict technical requirements. The Quectel modules have obtained certifications from the FCC, PCS Type Certification Review Board (PTCRB) and major carriers throughout the world, which underlines Quectel’s commitment to meeting rigorous industry standards.

In addition to cellular modules, Quectel also provides Wi-Fi, Bluetooth and GNSS modules and antennas. As a GSMA member, Quectel and its carrier partners comply with all cellular industry regulations and applicable standards to ensure that end customer data is securely transmitted between customer device and mobile network operator. Quectel does not have access to ANY of the device data.

Quectel is committed to delivering high-quality, best-in-class, secure modules and go above and beyond industry standard practices by conducting independent third-party cyber security audits. More recently Quectel also retained the security firm Finite State, which is auditing and penetration testing the security of its modules through rigorous security testing, improved software supply chain visibility, and comprehensive software risk management. Quectel is also participating in the formulation of new industry security certification standards, such as the CTIA Cybersecurity Certification Working Group and pursuing additional cyber security certifications from various U.S. entities as new standards are formulated and adopted.

Qualcomm manufactures the chipsets and software platforms that are at the core of the Quectel modules. “Our Qualcomm partnership underlines the importance we place on working with well-trusted and secure partners from across the ecosystem to deliver high-quality solutions globally,” Mr. Muhrer continues. “Quectel's impact on the global IoT industry is profound. We supplied millions of cellular modules to support the distribution of Covid-19 vaccines for leading U.S. and global organizations including Pfizer, Johnson & Johnson, and other leading suppliers of vaccines. This underscores our commitment to playing a pivotal role in critical global initiatives.”

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X (formerly known as Twitter).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: media@quectel.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye